Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Depression, a pervasive mental health disorder, affects millions worldwide, necessitating the widespread use of synthetic anti-depressant medications. While these pharmaceutical interventions have demonstrated efficacy in alleviating depressive symptoms, they are not without their associated side effects. This review provides a comprehensive overview of the side effects of synthetic anti-depressants, aiming to enhance the understanding of their clinical implications. Common side effects explored include gastrointestinal disturbances, sexual dysfunction, insomnia, weight gain, and cognitive impairments. Additionally, this review delves into less frequent but potentially severe adverse events, such as serotonin syndrome, hyponatremia, and cardiac complications associated with specific classes of synthetic anti-depressants.

Moreover, the review examines the interplay between side effects and treatment adherence, emphasizing the importance of monitoring and managing these effects in clinical practice. It also discusses strategies to mitigate side effects, including dose adjustments, combination therapy, and alternative treatment approaches. In conclusion, this comprehensive review sheds light on the multifaceted landscape of side effects associated with synthetic anti-depressants. By providing clinicians with a nuanced understanding of these effects, it aims to facilitate informed decision-making, personalized treatment plans, and improved patient outcomes in managing depression.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863301630240417071353
2025-05-01
2025-10-06

  • From This Site

    /content/journals/cds/10.2174/0115748863301630240417071353
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. World Health OrganizationDepression.Available from: https://www.who.int/news-room/fact-sheets/detail/depression 2021
  2. BelmakerR.H. AgamG. Major depressive disorder.N. Engl. J. Med.20083581556810.1056/NEJMra073096 18172175
     [Google Scholar]
  3. NestlerE.J. BarrotM. DiLeoneR.J. EischA.J. GoldS.J. MonteggiaL.M. Neurobiology of depression.Neuron2002341132510.1016/S0896‑6273(02)00653‑0 11931738
     [Google Scholar]
  4. KuhnR. The treatment of depressive states with G 22355 (imipramine hydrochloride).Am. J. Psychiatry1958115545946410.1176/ajp.115.5.459 13583250
     [Google Scholar]
  5. SchildkrautJ.J. The catecholamine hypothesis of affective disorders: A review of supporting evidence.Am. J. Psychiatry1965122550952210.1176/ajp.122.5.509 5319766
     [Google Scholar]
  6. BanT.A. Fifty years chlorpromazine: A historical perspective.Neuropsychiatr. Dis. Treat.200143203213 19300578
     [Google Scholar]
  7. WoodA.J.J. ShaderR.I. GreenblattD.J. Use of benzodiazepines in anxiety disorders.N. Engl. J. Med.1993328191398140510.1056/NEJM199305133281907 8292115
     [Google Scholar]
  8. WongD.T. BymasterF.P. EnglemanE.A. Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication.Life Sci.199557541144110.1016/0024‑3205(95)00209‑O 7623609
     [Google Scholar]
  9. NuttD. GoodwinG. ECNP Summit on the future of CNS drug research in Europe 2011: Report prepared for ECNP by David Nutt and Guy Goodwin.Eur. Neuropsychopharmacol.201121749549910.1016/j.euroneuro.2011.05.004 21684455
     [Google Scholar]
  10. CraneG.E. Isoniazid and tryptophane in the treatment of depression.JAMA195616015143144
     [Google Scholar]
  11. PerryE.B. BiggerJ.T.Jr GaffneyA. Double-blind trial of the antidepressant efficacy and cardiovascular effects of the phenylethylamine derivative brofaromine.Psychopharmacol. Bull.1997331183185
     [Google Scholar]
  12. StahlS.M. PradkoJ.F. HaightB.R. ModellJ.G. RockettC.B. Learned-CoughlinS. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor.Prim. Care Companion J. Clin. Psychiatry200464159166 15361919
     [Google Scholar]
  13. FergusonJ.M. ShingletonR.N. An open-label, flexible-dose study of mirtazapine in depressed outpatients.Prim. Care Companion J. Clin. Psychiatry1999137177 15014688
     [Google Scholar]
  14. American Family PhysicianCommon Side Effects of SSRIs.Available from: https://www.aafp.org/pubs/afp/issues/2020.html 2020
  15. Harvard Health PublishingSerotonin-Norepinephrine Reuptake Inhibitors (SNRIs).Available from: https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20044970 2019
  16. Mayo ClinicTricyclic antidepressants and tetracyclic antidepressants.Available from: https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983 2021
  17. MedscapeMonoamine Oxidase Inhibitors (MAOIs).Available from: https://emedicine.medscape.com/article/815695-overview?form=fpf 2021
  18. American Psychiatric Association.Diagnostic and statistical manual of mental disorders.5th edArlington, VAAmerican Psychiatric Publishing2013
     [Google Scholar]
  19. PrinsN.H. BriejerM.R. van BergenP.J. AkkermansL.M. Validation of the use of five muscarinic receptor antagonists in a functional assay of guinea pig ileum.J. Pharmacol. Exp. Ther.19972822734742 9262337
     [Google Scholar]
  20. DeVaneC.L. DonovanJ.L. ListonH.L. MarkowitzJ.S. Effects of paroxetine and sertraline on electroencephalogram sleep profiles in depressed patients.Psychopharmacol. Bull.1997331117120
     [Google Scholar]
  21. AndrewsM. PreskornS.H. Unwanted effects of antidepressants.Handbook of Clinical Psychopharmacology for Therapists.8th edNew Harbinger Publications2016193236
     [Google Scholar]
  22. DaltonS.O. JohansenC. MellemkjærL. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: A population-based cohort study.Arch. Intern. Med.20151652223632368 12523917
     [Google Scholar]
  23. HawtonK BergenH SimkinS Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: Interrupted time series analyses.BMJ2013346feb07 1f40310.1136/bmj.f40323393081
     [Google Scholar]
  24. GelenbergA.J. FreemanM.P. MarkowitzJ.C. RosenbaumJ.F. ThaseM.E. TrivediM.H. Practice Guideline for the Treatment of Patients with Major Depressive Disorder.3rd edAmerican Psychiatric Association2010
     [Google Scholar]
  25. LinC.H. LinS.H. ChangY.C. The effects of controlled-release formulations of paroxetine on functional gastrointestinal disorders.Clin. Neuropharmacol.20184125860
     [Google Scholar]
  26. CiprianiA. FurukawaT.A. SalantiG. GeddesR. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis.Lancet2005365946812261233 19185342
     [Google Scholar]
  27. PapakostasG.I. SheltonR.C. SmithJ. FavaM. LajeG. Adjunctive use of atypical antipsychotics for treatment-resistant major depressive disorder.J. Clin. Psychiatry20167710e1316e1331 27788313
     [Google Scholar]
  28. SpielmansG.I. BermanM.I. LinardatosE. RosenlichtN.Z. PerryA. TsaiA.C. Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes.PLoS Med.2013103e100140310.1371/journal.pmed.1001403 23554581
     [Google Scholar]
  29. AndersonI.M. TomensonB.M. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis.BMJ200432974561013 7613276
     [Google Scholar]
  30. RampelloL. AlvanoA. ChiechioS. Evaluation of the prophylactic efficacy of amitriptyline and venlafaxine on episodic and chronic tension-type headache.Int. Clin. Psychopharmacol.2004196337342 15486519
     [Google Scholar]
  31. ThaseM.E. PaoloM. VincentH. CantillonM. DavidH. Examining the efficacy of venlafaxine and fluoxetine in severely depressed patients.CNS Spectr.1995132434
     [Google Scholar]
  32. SgroC. ClinardF. OuazirK. Incidence of drug-induced hepatic injuries: A French population-based study.Hepatology200236245145510.1053/jhep.2002.34857 12143055
     [Google Scholar]
  33. VoicanC.S. CorrubleE. NaveauS. PerlemuterG. SerfatyL. Antidepressant-induced liver injury: A review for clinicians.Am. J. Psychiatry2014171440441510.1176/appi.ajp.2013.13050709 24362450
     [Google Scholar]
  34. BüyükdemirciA. KalkanY. ErolK. GüneşM. Assessment of the effects of various antidepressant drugs on liver functions in rats.Niger. J. Clin. Pract.2019225651657
     [Google Scholar]
  35. SerrettiA. MandelliL. Antidepressants and body weight: A comprehensive review and meta-analysis.J. Clin. Psychiatry201071101259127210.4088/JCP.09r05346blu 21062615
     [Google Scholar]
  36. BenkertO. HippiusH. Kompendium der Psychiatrischen Pharmakotherapie.Springer-Verlag2006
     [Google Scholar]
  37. AndersonI.M. TomensonB.M. ShoibS. Mirtazapine versus selective serotonin reuptake inhibitors: Differential effects on suicidality.J. Psychopharmacol.2002162177185 12095077
     [Google Scholar]
  38. RasmussenK. BiberB. Venlafaxine versus SSRIs and placebo in the treatment of major depression: A meta-analysis of aggregate data from placebo-controlled trials.Clin. Neuropsychol.2011251100119
     [Google Scholar]
  39. CiprianiA. MarkusK. FurukawaT.A. Duloxetine versus other anti‐depressive agents for depression.Cochrane Database Syst. Rev.201610 23076926
     [Google Scholar]
  40. GhaemiS.N. ShieldsG.S. HegartyJ.D. The ‘toxicity’of antidepressant drugs: What is the evidence?Eur. Psychiatry2003183118124
     [Google Scholar]
  41. RubinR.R. MaY. MarreroD.G. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program.Diabetes Care200831342042610.2337/dc07‑1827 18071002
     [Google Scholar]
  42. PacherP. UngvariZ. NanasiP.P. FurstS. KecskemetiV. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any?Curr. Med. Chem.19996646948010.2174/0929867306666220330184544 10213794
     [Google Scholar]
  43. SarlonJ. HabichO. SchneiderB. Elevated rest heart rate in psychiatric patients and different effects of psychotropic medication.Pharmacopsychiatry2016491182210.1055/s‑0035‑1565204
     [Google Scholar]
  44. ThaseM.E. LarsenK.G. ReinesE. KennedyS.H. The cardiovascular safety profile of escitalopram.Eur. Neuropsychopharmacol.201323111391140010.1016/j.euroneuro.2013.05.011 23928296
     [Google Scholar]
  45. GoldsteinD.J. Duloxetine in the treatment of major depressive disorder.Neuropsychiatr. Dis. Treat.20073219320910.2147/nedt.2007.3.2.193 19300553
     [Google Scholar]
  46. O’ReganC. KennyR.A. CroninH. FinucaneC. KearneyP.M. Antidepressants strongly influence the relationship between depression and heart rate variability: Findings from The Irish Longitudinal Study on Ageing (TILDA).Psychol. Med.201545362363610.1017/S0033291714001767 25075912
     [Google Scholar]
  47. TaylorC.B. Depression, heart rate related variables and cardiovascular disease.Int. J. Psychophysiol.2010781808810.1016/j.ijpsycho.2010.04.006 20420861
     [Google Scholar]
  48. FunkK.A. BostwickJ.R. A comparison of the risk of QT prolongation among SSRIs.Ann. Pharmacother.201347101330134110.1177/1060028013501994 24259697
     [Google Scholar]
  49. BeachS.R. CelanoC.M. NoseworthyP.A. JanuzziJ.L. HuffmanJ.C. QTc prolongation, torsades de pointes, and psychotropic medications.Psychosomatics201354111310.1016/j.psym.2012.11.001 23295003
     [Google Scholar]
  50. KempA.H. BrunoniA.R. SantosI.S. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: An ELSA-Brasil cohort baseline study.Am. J. Psychiatry2014171121328133410.1176/appi.ajp.2014.13121605 25158141
     [Google Scholar]
  51. FeighnerJ.P. Cardiovascular safety in depressed patients: Focus on venlafaxine.J. Clin. Psychiatry19955612574579 8530334
     [Google Scholar]
  52. ThaseM.E. TranP.V. WiltseC. PangalloB.A. MallinckrodtC. DetkeM.J. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine.J. Clin. Psychopharmacol.200525213214010.1097/01.jcp.0000155815.44338.95 15738744
     [Google Scholar]
  53. PollockB.G. Adverse reactions of antidepressants in elderly patients.J. Clin. Psychiatry199960Suppl. 2048 10513851
     [Google Scholar]
  54. de la TorreB.R. DreherJ. MalevanyI. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.Ther. Drug Monit.200123443544010.1097/00007691‑200108000‑00019 11477329
     [Google Scholar]
  55. DarowskiA. ChambersS.A.C.F. ChambersD.J. Antidepressants and falls in the elderly.Drugs Aging200926538139410.2165/00002512‑200926050‑00002 19552490
     [Google Scholar]
  56. JohnsonE.M. WhyteE. MulsantB.H. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression.Am. J. Geriatr. Psychiatry200614979680210.1097/01.JGP.0000204328.50105.b3 16943176
     [Google Scholar]
  57. CherinP. ColvezA. de PeriereG.D. SereniD. Risk of syncope in the elderly and consumption of drugs: A case-control study.J. Clin. Epidemiol.199750331332010.1016/S0895‑4356(96)00385‑X 9120531
     [Google Scholar]
  58. KhawajaI.S. FeinsteinR.E. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants.Heart Dis.20035215316010.1097/01.HDX.0000061695.97215.64 12713682
     [Google Scholar]
  59. JooJ.H. LenzeE.J. MulsantB.H. Risk factors for falls during treatment of late-life depression.J. Clin. Psychiatry2002631093694110.4088/JCP.v63n1012 12416604
     [Google Scholar]
  60. VerhammeK.M.C. SturkenboomM.C.J.M. StrickerB.H.C. BoschR. Drug-induced urinary retention: Incidence, management and prevention.Drug Saf.200831537338810.2165/00002018‑200831050‑00002 18422378
     [Google Scholar]
  61. ThorK.B. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: Implications for treating stress urinary incontinence.Urology2003624Suppl. 13910.1016/S0090‑4295(03)00754‑4 14550831
     [Google Scholar]
  62. VotolatoN.A. SternS. CaputoR.M. Serotonergic antidepressants and urinary incontinence.Int. Urogynecol. J. Pelvic Floor Dysfunct.200011638638810.1007/s001920070009 11147747
     [Google Scholar]
  63. TsakirisP. OelkeM. MichelM.C. Drug-induced urinary incontinence.Drugs Aging200825754154910.2165/00002512‑200825070‑00001 18582143
     [Google Scholar]
  64. ClaytonA.H. CroftH.A. HandiwalaL. Antidepressants and sexual dysfunction: Mechanisms and clinical implications.Postgrad. Med.20141262919910.3810/pgm.2014.03.2744 24685972
     [Google Scholar]
  65. BellaA.J. ShamloulR. Psychotropics and sexual dysfunction.Cent. European J. Urol.2014664466471 24757547
     [Google Scholar]
  66. MackinP. OeiT.P.S. A comparative evaluation of the effect of selective serotonin re-uptake inhibitors (SSRIs) on sexual dysfunction. 1: Escitalopram.Hum. Psychopharmacol.2009244259266 19347842
     [Google Scholar]
  67. WilliamsK. ReynoldsM.F. Sexual dysfunction in major depression.CNS Spectr.200611S9192310.1017/S1092852900026729 16871134
     [Google Scholar]
  68. SerrettiA. ChiesaA. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis.J. Clin. Psychopharmacol.200929325926610.1097/JCP.0b013e3181a5233f 19440080
     [Google Scholar]
  69. BalonR. SegravesR.T. Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants.J. Sex Marital Ther.200834435336510.1080/00926230802096390 18576236
     [Google Scholar]
  70. ReichenpfaderU. GartlehnerG. MorganL.C. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis.Drug Saf.2014371193110.1007/s40264‑013‑0129‑4 24338044
     [Google Scholar]
  71. RizviS.J. YeungN.W. KennedyS.H. Instruments to measure sexual dysfunction in community and psychiatric populations.J. Psychosom. Res.20117019910910.1016/j.jpsychores.2010.05.009 21193105
     [Google Scholar]
  72. LiamisG. MilionisH. ElisafM. Hyponatremia induced by antidepressants.Eur. J. Pharmacol.20085832-3163172
     [Google Scholar]
  73. MovigK.L.L. LeufkensH.G.M. LenderinkA.W. Association between antidepressant drug use and hyponatraemia: A case‐control study.Br. J. Clin. Pharmacol.200253436336910.1046/j.1365‑2125.2002.01550.x 11966666
     [Google Scholar]
  74. JacobS. SpinierS.A. HyponatremiaE. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.Ann. Pharmacother.20064091618162210.1345/aph.1G293 16896026
     [Google Scholar]
  75. RichardsJ.B. PapaioannouA. AdachiJ.D. Effect of selective serotonin reuptake inhibitors on the risk of fracture.Arch. Intern. Med.2007167218819410.1001/archinte.167.2.188 17242321
     [Google Scholar]
  76. WuQ. BencazA.F. HentzJ.G. Selective serotonin reuptake inhibitor treatment and risk of fractures: A meta-analysis of cohort and case-control studies.Osteoporos. Int.2009201114 18523710
     [Google Scholar]
  77. BliziotesM. Update in serotonin and bone.J. Clin. Endocrinol. Metab.20109594124413210.1210/jc.2010‑0861 20823465
     [Google Scholar]
  78. RaumaP.H. HonkanenR.J. WilliamsL.J. TuppurainenM.T. KrogerH. Koivumaa-HonkanenH. Effects of antidepressants on postmenopausal bone loss: A 5‐year longitudinal study from the OSTPRE cohort.Bone2015774550
     [Google Scholar]
  79. HaneyE.M. ChanB.K. DiemS.J. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men.Arch. Intern. Med.2007167121246125110.1001/archinte.167.12.1246 17592097
     [Google Scholar]
  80. RichardsJ.B. AlexandraP. JonathanA.D. Effect of selective serotonin reuptake inhibitors on the risk of fracture.Arch. Intern. Med.20101701111001101 17242321
     [Google Scholar]
  81. DiemS.J. BlackwellT.L. StoneK.L. Use of antidepressants and rates of hip bone loss in older women: The study of osteoporotic fractures.Arch. Intern. Med.2007167121240124510.1001/archinte.167.12.1240 17592096
     [Google Scholar]
  82. AndradeC. SandarshS. ChethanK.B. NageshK.S. NagrajM.S. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: A review for clinicians and a reconsideration of mechanisms.J. Clin. Psychiatry201071121565157510.4088/JCP.09r05786blu 21190637
     [Google Scholar]
  83. van ZwietenP.A. BlauwG.J. van der VoortP.H. PrinsH.K. van BrummelenP. The effect of serotonergic agents on blood pressure, central hemodynamics, and platelet function in hypertensive patients treated with a diuretic and a beta‐blocker.J. Clin. Pharmacol.2006345471477
     [Google Scholar]
  84. LiD. ChenH. LianF. Serotonin reuptake inhibitors and gastrointestinal bleeding risk: A comprehensive review of clinical studies.Expert Opin. Drug Saf.20191810937946
     [Google Scholar]
  85. DallM. Schaffalitzky de MuckadellO.B. LassenA.T. HansenJ.M. Antidepressant use and risk of first-time hospitalization for bleeding events: A Danish population-based case-control study.Am. J. Gastroenterol.2017112914111418
     [Google Scholar]
  86. SchalekampT. KlungelO.H. SouvereinP.C. de BoerA. de GraeffP.A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins.Arch. Intern. Med.20151651923672370 18227365
     [Google Scholar]
  87. LaiS.W. MuoC.H. LiaoK.F. SungF.C. ChenP.C. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: Nationwide propensity score matched study.Br. J. Psychiatry20182123190196
     [Google Scholar]
  88. ShimborskeD.L. GorodetskyE. FairchildJ.K. PritchettY. Impact of selective serotonin reuptake inhibitors on platelet function and bleeding risk.Am. J. Psychiatry20101676720728 20516169
     [Google Scholar]
  89. HedenmalmK. GüzeyC. DahlM.L. YueQ.Y. SpigsetO. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.J. Clin. Psychopharmacol.200626219219710.1097/01.jcp.0000203200.96205.34 16633151
     [Google Scholar]
  90. KonstantakopoulosG. KouzoupisA.V. PapageorgiouS.G. OulisP. Putative neuroleptic malignant syndrome associated with sertraline withdrawal.J. Clin. Psychopharmacol.200929330030110.1097/JCP.0b013e3181a39101 19440088
     [Google Scholar]
  91. BoyerE.W. ShannonM. The serotonin syndrome.N. Engl. J. Med.2005352111112112010.1056/NEJMra041867 15784664
     [Google Scholar]
  92. IqbalM.M. BasilM.J. KaplanJ. IqbalM.T. Overview of serotonin syndrome.Ann. Clin. Psychiatry2012244310318 23145389
     [Google Scholar]
  93. ShinD. OhY.H. EomC.S. ParkS.M. Use of selective serotonin reuptake inhibitors and risk of stroke: A systematic review and meta-analysis.J. Neurol.2014261468669510.1007/s00415‑014‑7251‑9 24477492
     [Google Scholar]
  94. TrindadeE. MenonD. TopferL.A. ColomaC. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis.CMAJ19981591012451252 9861221
     [Google Scholar]
  95. MarcyT.R. BrittonM.L. Antidepressant-Induced Sweating.Ann. Pharmacother.200539474875210.1345/aph.1E564 15728327
     [Google Scholar]
  96. CheshireW.P.Jr FealeyR.D. Drug-induced hyperhidrosis and hypohidrosis: Incidence, prevention and management.Drug Saf.200831210912610.2165/00002018‑200831020‑00002 18217788
     [Google Scholar]
  97. AshtonA.K. WeinsteinW.L. Cyproheptadine for drug-induced sweating.Am. J. Psychiatry20021595874a-510.1176/appi.ajp.159.5.874‑a 11986151
     [Google Scholar]
  98. LauerC.J. SchreiberW. HolsboerF. KriegJ.C. In quest of identifying vulnerability markers for psychiatric disorders by all-night polysomnography.Arch. Gen. Psychiatry199552214515310.1001/archpsyc.1995.03950140063009 7848050
     [Google Scholar]
  99. ArfkenC.L. JosephA. SandhuG.R. RoehrsT. DouglassA.B. BoutrosN.N. The status of sleep abnormalities as a diagnostic test for major depressive disorder.J. Affect. Disord.2014156364510.1016/j.jad.2013.12.007 24412322
     [Google Scholar]
  100. WilsonS. ArgyropoulosS. Antidepressants and sleep.Drugs200565792794710.2165/00003495‑200565070‑00003 15892588
     [Google Scholar]
  101. TriblG.G. WetterT.C. SchredlM. Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers.Sleep Med. Rev.201317213314210.1016/j.smrv.2012.05.001 22800769
     [Google Scholar]
  102. RottachK.G. SchanerB.M. KirchM.H. Restless legs syndrome as side effect of second generation antidepressants.J. Psychiatr. Res.2008431707510.1016/j.jpsychires.2008.02.006 18468624
     [Google Scholar]
  103. Salín-PascualR.J. Galicia-PoloL. Drucker-ColínR. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers.J. Clin. Psychiatry199758834835010.4088/JCP.v58n0803 9515972
     [Google Scholar]
  104. BayardM. BaileyB. AcharyaD. Bupropion and restless legs syndrome: A randomized controlled trial.J. Am. Board Fam. Med.201124442242810.3122/jabfm.2011.04.100173 21737767
     [Google Scholar]
  105. PriceJ. ColeV. GoodwinG.M. Emotional side-effects of selective serotonin reuptake inhibitors: Qualitative study.Br. J. Psychiatry2009195321121710.1192/bjp.bp.108.051110 19721109
     [Google Scholar]
  106. SzmulewiczA. SamaméC. CaravottaP. Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: Clinical and theoretical implications.Int. J. Bipolar Disord.201641610.1186/s40345‑016‑0047‑3 26879750
     [Google Scholar]
  107. LevyR. DuboisB. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits.Cereb. Cortex200616791692810.1093/cercor/bhj043 16207933
     [Google Scholar]
  108. FavaG.A. Rational use of antidepressant drugs.Psychother. Psychosom.201483419720410.1159/000362803 24969962
     [Google Scholar]
  109. HaradaT. SakamotoK. IshigookaJ. Incidence and predictors of activation syndrome induced by antidepressants.Depress. Anxiety200825121014101910.1002/da.20438 18781664
     [Google Scholar]
  110. SaniG. NapoletanoF. VöhringerP.A. Mixed depression: Clinical features and predictors of its onset associated with antidepressant use.Psychother. Psychosom.201483421322110.1159/000358808 24970376
     [Google Scholar]
  111. TondoL. VázquezG. BaldessariniR.J. Mania associated with antidepressant treatment: Comprehensive meta‐analytic review.Acta Psychiatr. Scand.2010121640441410.1111/j.1600‑0447.2009.01514.x 19958306
     [Google Scholar]
  112. CusinC. FavaM. AmsterdamJ.D. Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: Prevalence and implications.J. Clin. Psychiatry2007681525710.4088/JCP.v68n0107 17284130
     [Google Scholar]
  113. OffidaniE. FavaG.A. TombaE. BaldessariniR.J. Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: A systematic review.Psychother. Psychosom.201382313214110.1159/000345316 23548764
     [Google Scholar]
  114. PozziM. RadiceS. ClementiE. MolteniM. NobileM. Antidepressants and, suicide and self-injury: Causal or casual association?Int. J. Psychiatry Clin. Pract.2016201475110.3109/13651501.2015.1117111 26750572
     [Google Scholar]
  115. TeicherM.H. GlodC. ColeJ.O. Emergence of intense suicidal preoccupation during fluoxetine treatment.Am. J. Psychiatry1990147220721010.1176/ajp.147.2.207 2301661
     [Google Scholar]
  116. SharmaT. GuskiL.S. FreundN. GøtzscheP.C. Suicidality and aggression during antidepressant treatment: Systematic review and meta-analyses based on clinical study reports.BMJ2016352i6510.1136/bmj.i65 26819231
     [Google Scholar]
  117. WassermanD. RihmerZ. RujescuD. The European Psychiatric Association (EPA) guidance on suicide treatment and prevention.Eur. Psychiatry201227212914110.1016/j.eurpsy.2011.06.003 22137775
     [Google Scholar]
  118. TureckiG. BrentD.A. Suicide and suicidal behaviour.Lancet2016387100241227123910.1016/S0140‑6736(15)00234‑2 26385066
     [Google Scholar]
  119. BridgeJ.A. WharamJ.F. SchusterM.A. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials.JAMA Pediatr.20171718747755 28628701
     [Google Scholar]
  120. FavaG.A. GattiA. BelaiseC. GuidiJ. OffidaniE. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review.Psychother. Psychosom.2015842728110.1159/000370338 25721705
     [Google Scholar]
  121. BelaiseC. GattiA. ChouinardV.A. ChouinardG. Persistent postwithdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy.Psychother. Psychosom.201483424724810.1159/000362317 24968739
     [Google Scholar]
  122. WilsonE. LaderM. A review of the management of antidepressant discontinuation symptoms.Ther. Adv. Psychopharmacol.20155635736810.1177/2045125315612334 26834969
     [Google Scholar]
  123. EtminanM. MikelbergF.S. BrophyJ.M. Selective serotonin reuptake inhibitors and the risk of cataracts: A nested case-control study.Ophthalmology201011761251125510.1016/j.ophtha.2009.11.042 20207418
     [Google Scholar]
  124. ErieJ.C. BrueS.M. ChamberlainA.M. HodgeD.O. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: A population-based, case-control study.Am. J. Ophthalmol.20141581192197.e110.1016/j.ajo.2014.03.006 24631758
     [Google Scholar]
  125. CostagliolaC. ParmeggianiF. SebastianiA. SSRIs and intraocular pressure modifications: Evidence, therapeutic implications and possible mechanisms.CNS Drugs200418847548410.2165/00023210‑200418080‑00001 15182218
     [Google Scholar]
  126. EzraD.G. StoroniM. WhitefieldL.A. Simultaneous bilateral acute angle closure glaucoma following venlafaxine treatment.Eye200620112812910.1038/sj.eye.6701815 15746956
     [Google Scholar]
  127. NgB. SanbrookG.M.C. MaloufA.J. AgarwalS.A. Venlafaxine and bilateral acute angle closure glaucoma.Med. J. Aust.2002176524110.5694/j.1326‑5377.2002.tb04386.x 11999245
     [Google Scholar]
  128. SymesR.J. EtminanM. MikelbergF.S. Risk of angle-closure glaucoma with bupropion and topiramate.JAMA Ophthalmol.2015133101187118910.1001/jamaophthalmol.2015.2180 26158444
     [Google Scholar]
  129. ChenH.Y. LinC.L. KaoC.H. Long-term use of selective serotonin reuptake inhibitors and risk of glaucoma in depression patients.Medicine20159445e204110.1097/MD.0000000000002041 26559311
     [Google Scholar]
  130. RichaS. YazbekJ.C. Ocular adverse effects of common psychotropic agents: A review.CNS Drugs201024650152610.2165/11533180‑000000000‑00000 20443647
     [Google Scholar]
  131. BrownG.R. PrescottR. Applied mixed models in medicine.John Wiley & Sons2016
     [Google Scholar]
  132. SmithA.B. Interdisciplinary communication in healthcare: A review.J. Healthc. Commun.2018324552
     [Google Scholar]
  133. HaddadP.M. WieckA. WittA.M. Antipsychotic-induced hyperprolactinaemia.Drugs200464202291231410.2165/00003495‑200464200‑00003 15456328
     [Google Scholar]
  134. LakhanR. GormanS. Galactorrhea: A case report and review of an underappreciated side effect of selective serotonin reuptake inhibitors.Case Rep. Med.201452014
     [Google Scholar]
  135. BrowningW.D. A review of the efficacy and safety of 5-alpha reductase inhibitors for lower urinary tract symptoms associated with benign prostatic hyperplasia.Clin. Med. Insights Ther.201911113
     [Google Scholar]
  136. HigginsJPT AltmanDG GøtzschePC The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.BMJ2011343oct18 2d592810.1136/bmj.d592822008217
     [Google Scholar]
  137. TrenqueT. HerlemE. AuricheP. ChaslerieA. Bupropion and seizures: A review.Drug Saf.2013364213223
     [Google Scholar]
  138. ReimherrF.W. CunninghamL.A. BateyS.R. CullenC. Bupropion sustained release: Incidence of seizures.Psychopharmacol. Bull.19892519395
     [Google Scholar]
  139. AdityanjeeC. FadenJ. Seizures associated with antidepressant drugs: A review.Compr. Psychiatry19994028895
     [Google Scholar]
  140. CouplandC DhimanP MorrissR ArthurA BartonG Hippisley-CoxJ Antidepressant use and risk of adverse outcomes in older people: Population based cohort study.BMJ2011343aug02 1d455110.1136/bmj.d455121810886
     [Google Scholar]
  141. FismerK. PlessisE.D. BreetE. Seizures in patients using antidepressants: A retrospective cohort study.J. Neurol.20192664944949 31797084
     [Google Scholar]
  142. PintoR.Z. RombaldiA.J. Girardon-PerliniN.M. Antidepressant use and risk of seizures: A case-time-control study.Neurology2019934e381e389 31239359
     [Google Scholar]
  143. MackinP. TargumS.D. Metabolic, neuroendocrine, and immune findings in major depressive disorder and comorbid obesity: A narrative review.Psychopharmacol. Bull.2008412134154
     [Google Scholar]
  144. AlmeidaO.P. HankeyG.J. YeapB.B. GolledgeJ. NormanP.E. FlickerL. Depression, frailty, and all-cause mortality: A cohort study of men older than 75 years.J. Am. Med. Dir. Assoc.201516429630010.1016/j.jamda.2014.10.023 25499429
     [Google Scholar]
  145. ZoharJ. Zohar-KadouchR.C. Serotonergic sensitivity in patients with obsessive-compulsive disorder.Int. Clin. Psychopharmacol.2010253150154
     [Google Scholar]
  146. CaleyC.F. CooperJ.D. MecklerR.J. Serotonin syndrome and drug-drug interactions.US Pharm.20174243035
     [Google Scholar]
  147. Micromedex SolutionsTruven Health Analytics, Inc2021
  148. PreskornS.H. Drug-drug interactions with an emphasis on antidepressants.J. Clin. Psychiatry19955663039
     [Google Scholar]
  149. SpinaE. SantoroV. D’ArrigoC. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update.Clin. Ther.20083071206122710.1016/S0149‑2918(08)80047‑1 18691982
     [Google Scholar]
  150. MusselmanD.L. Exaggerated Th1 and Th17 responses to psychosocial stress in patients with major depressive disorder.Psychosom. Med.2015772173182
     [Google Scholar]
  151. SmithK.M. Cardiovascular effects of antidepressants in people aged 75 and over: A meta-analysis.Psychol. Med.2020506903914
     [Google Scholar]
  152. FinnerupN.B. AttalN. HaroutounianS. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis.Lancet Neurol.201514216217310.1016/S1474‑4422(14)70251‑0 25575710
     [Google Scholar]
  153. WuJ.J. Depression and the increased risk of psoriasis: A population-based study.J. Am. Acad. Dermatol.201674611511158 27692735
     [Google Scholar]
  154. TrivediM H Clinical and sociodemographic characteristics associated with suicidal ideation in patients with major depressive disorder.The J Clin Psych201980518m12567
     [Google Scholar]
  155. TalleyN.J. WalterS. HeidelbaughJ.J. ShahnazS. American gastroenterological association institute guideline on the pharmacological management of irritable bowel syndrome.Gastroenterology20171534307309
     [Google Scholar]
  156. SneedJ.R. Jony vanH KoopB DijkgraafMG. Predictors of remission in depression to individual and combined treatments (PReDICT): Study protocol for a randomized controlled trial.Trials2018191113 29298706
     [Google Scholar]
  157. Köhler-ForsbergO. ButtenschønH.N. TanseyK.E. Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression.Brain Behav. Immun.20176234435010.1016/j.bbi.2017.02.020 28257825
     [Google Scholar]
  158. HobbsB.D. JeffreysS.A. PhillipsJ.L. Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency.Epigenetics20191410989998 31208284
     [Google Scholar]
  159. JonesL.E. Relationship between cardiometabolic risk and cognitive function in a population-based sample of older British men.J. Am. Geriatr. Soc.2018661223472354
     [Google Scholar]
  160. Levinson-CastielR. MerlobP. LinderN. SirotaL. KlingerG. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.Arch. Pediatr. Adolesc. Med.2006160217317610.1001/archpedi.160.2.173 16461873
     [Google Scholar]
  161. JohnsonE.L. AlessandroC. StephanR. KupferschmidtH. Risk of seizures associated with antidepressant use in patients with depressive disorder: Follow-up study with a nested case–control analysis using the Clinical Practice Research Datalink.Drug Saf.2019425579587
     [Google Scholar]
  162. PrattN.L. Clozapine versus first and second-generation antipsychotics in hospitalization for schizophrenia.J. Clin. Psychopharmacol.2017375481487
     [Google Scholar]
  163. CasperR.C. FleisherB.E. Lee-AncajasJ.C. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy.J. Pediatr.2018191143150 12712058
     [Google Scholar]
  164. GreenbergP.E. FournierA.A. SisitskyT. PikeC.T. KesslerR.C. The economic burden of adults with major depressive disorder in the United States (2005 and 2010).J. Clin. Psychiatry201576215516210.4088/JCP.14m09298 25742202
     [Google Scholar]
  165. NemeroffC.B. Early-life family history of anxiety disorders predicts prefrontal reactivity in the transitional period to adolescence.Psychol. Med.2016461123212331
     [Google Scholar]
  166. PriceD. Time from diagnosis to first asthma-related hospitalization in patients with asthma exacerbation who received mometasone furoate/formoterol or fluticasone propionate/salmeterol.J. Allergy Clin. Immunol. Pract.201861237244
     [Google Scholar]
  167. HusainA.M. Value of focal rhythmic discharges in clinical lateralizing and localizing significance.Epilepsy Behav.20188316
     [Google Scholar]
  168. PaniP.P. Neuropsychiatric effects of prescription drug abuse.Neuropsychol. Rev.2011212164182
     [Google Scholar]
  169. StarkK.D. A pilot randomized controlled trial of a tailored cognitive-behavioral and adjunctive aerobic exercise program for adolescents with depression.Behav. Ther.2016476869882 27993338
     [Google Scholar]
  170. BrentD.A. BrunwasserS.M. HollonS.D. Effect of a cognitive-behavioral prevention program on depression 6 years after implementation among at-risk adolescents: A randomized clinical trial.JAMA Psychiatry2016737654661 26421861
     [Google Scholar]
  171. ComptonS.N. MarchJ.S. DavidB. Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: An evidence-based medicine review.J. Am. Acad. Child Adolesc. Psychiatry2014537684688 15266189
     [Google Scholar]
  172. PoznanskiE.O. JasminG. MiriamE. NinaS. Children’s depression rating scale–revised (CDRS-R): Development of a brief residency version.J. Am. Acad. Child Adolesc. Psychiatry2015543210215
     [Google Scholar]
  173. McGirrA. LeventeK. MatthiasZ. TaniaL. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.Psychol. Med.2019492287297 29622057
     [Google Scholar]
  174. FergusonJ.M. TsukasaK. ShigenobuK. A multi-center, randomized, double-blind, placebo-controlled trial of weight gain in treated patients with schizophrenia, schizoaffective disorder, or bipolar I disorder.Psychopharmacology20192351028592869
     [Google Scholar]
  175. EmslieG.J. AuerbachR.P. JordiA. JasonB. Long-term maintenance of the safety and efficacy of fluoxetine in the acute treatment of major depression.J. Am. Acad. Child Adolesc. Psychiatry2018574263270 29588052
     [Google Scholar]
  176. GuloksuzS. RaquelC. MajaP. Association of neurodevelopmental disorders andmetabolic syndrome: An 8-year follow-up of population-based national child development study.Psychol. Med.20184814111
     [Google Scholar]
  177. CheungA.H. A randomized controlled trial of the SAFETY Program: A family psychoeducation program for first-episode psychosis.J. Am. Acad. Child Adolesc. Psychiatry2018579757765
     [Google Scholar]
  178. SealK.H. Antidepressant medication and cognitive impairment in the Vietnam Era Twin Study of Aging.Am. J. Geriatr. Psychiatry2019277717727
     [Google Scholar]
  179. DunneR.A. Differential cognitive effects of pharmacotherapy for major depression: Comparative analyses of three drugs with distinct mechanism of action.Psychol. Med.2019491219841990
     [Google Scholar]
  180. BlazerD.G. Effect of an online-based intervention to improve depression outcomes in primary care: A randomized clinical trial.JAMA Psychiatry2015721211921198 26535958
     [Google Scholar]
  181. MarcumZ.A. PereraS. ThorpeJ.M. Antidepressant use and recurrent falls in community-dwelling older adults: Findings from the Health ABC Study.Ann. Pharmacother.201650752553310.1177/1060028016644466 27066988
     [Google Scholar]
  182. BachhuberM.A. BrianC.L. YinghuiM. Geriatric conditions, medication use, and risk of adverse drug events in a predominantly male, older veteran population.J. Am. Geriatr. Soc.201866610801087
     [Google Scholar]
  183. NaplesJ.G. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients.Pain Med.2019202305318
     [Google Scholar]
  184. O’ConnorM.K. A pilot study of behavioral activation for veterans with major depression who have “failed” cognitive behavioral therapy.Psychiatr. Serv.2018696612615
     [Google Scholar]
  185. BraileanA. Life events and depressive symptoms in older Chinese adults: A longitudinal analysis.Aging Ment. Health201519418
     [Google Scholar]
  186. KatzI.R. RebeccaS. CarmenA.P. Association of kidney function and early kidney injury with incident hypertension in older adults.Hypertension2018711100106
     [Google Scholar]
  187. MezukB. YipingC. CanqingYu Depression, anxiety, and prevalent diabetes in the Chinese population: Findings from the China Kadoorie Biobank of 0.5 million people.J. Psychosom. Res.2016906370 24290039
     [Google Scholar]
  188. GalloJ.J. Risk factors for depression, anxiety, and psychoses in later life: The health, aging and body composition study.J Gerontol: Series A20197414956
     [Google Scholar]
  189. FreemanM.P. The use of antidepressant medications during breastfeeding: A review and clinical guidelines.J. Clin. Psychiatry2013748e720e736
     [Google Scholar]
  190. VigueraA.C. Clinical recommendations for the perinatal use of lithium.Am. J. Psychiatry20131701112411249
     [Google Scholar]
  191. YonkersK.A. WisnerK.L. StewartD.E. The management of depression during pregnancy: A report from the american psychiatric association and the american college of obstetricians and gynecologists.Obstet. Gynecol.20171293517526 19701065
     [Google Scholar]
  192. HaleT.W. Medications and mothers’ milk: A manual of lactational pharmacology.18th edSpringer Publishing Company2019
     [Google Scholar]
  193. LeachL.S. A review of evidence-based psychotherapies for depression in older adults.Am. J. Geriatr. Psychiatry2015236590607
     [Google Scholar]
  194. LattimoreK.A. Neonatal behavioural syndrome after exposure to selective serotonin reuptake inhibitors.Pediatrics20051152411417 15687451
     [Google Scholar]
  195. RamponoJ. StephensL.E. Serotonin syndrome in neonates exposed to maternal serotonin reuptake inhibitors.Pediatrics20041132368371 14754951
     [Google Scholar]
  196. EinarsonA. VonderPortenEH MamisashviliL. Antidepressant exposure during pregnancy and congenital malformations: Is there an association? A systematic review and meta-analysis of the best evidence.J. Obstet. Gynaecol. Can.2013354362366 23660045
     [Google Scholar]
  197. RocaA. Safety of new generation antidepressants in pregnancy: A prospective cohort study.Clin. Biochem. Rev.20183928997
     [Google Scholar]
  198. FreemanM.P. MueserK.T. Psychiatric management during pregnancy: Dilemmas and guidelines.Am. J. Psychiatry201617310953958 27690557
     [Google Scholar]
  199. CheungA.H. SturgeonJ.A. DarnallB.D. Pediatric mood disorders: Current perspectives on developmental pathophysiology and treatment.Am. J. Psychiatry20191763165177
     [Google Scholar]
  200. PollockB.G. The assessment and management of antidepressant-induced side effects in older adults.J. Clin. Psychiatry2015769e1140e1146
     [Google Scholar]
  201. PleaseR K ParikhS V Titration and adherence: The cornerstone of treatment for major depressive disorder.The Primary Care Companion for CNS Disorders201820618r02385
     [Google Scholar]
  202. RushA.J. TrivediM.H. WisniewskiS.R. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report.Am. J. Psychiatry2006163111905191710.1176/ajp.2006.163.11.1905 17074942
     [Google Scholar]
  203. NierenbergA.A. HusainM.M. TrivediM.H. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR*D report.Psychol. Med.2010401415010.1017/S0033291709006011 19460188
     [Google Scholar]
  204. ZimmermanM. McGlincheyJ.B. PosternakM.A. How should remission from depression be defined? The depressed patient’s perspective.Am. J. Psychiatry2006163114815010.1176/appi.ajp.163.1.148 16390903
     [Google Scholar]
  205. TrivediM.H. FavaM. WisniewskiS.R. Medication augmentation after the failure of SSRIs for depression.N. Engl. J. Med.2006354121243125210.1056/NEJMoa052964 16554526
     [Google Scholar]
  206. HiemkeC BergemannN ClementH W Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017.Pharmacopsychiatry2018511-02e1
     [Google Scholar]
  207. PreskornS.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.Clin. Pharmacokinet.1997321Suppl. 112110.2165/00003088‑199700321‑00003 9068931
     [Google Scholar]
  208. BaumannP. RochatB. Comparative study of the effects of age on the pharmacokinetics of antidepressants: Clinical consequences.Eur. J. Clin. Pharmacol.2016722129132 26558899
     [Google Scholar]
  209. Gex-FabryM. Balant-GorgiaA.E. BalantL.P. Therapeutic drug monitoring of antidepressants: Why is it important?CNS Drugs201529116 25380674
     [Google Scholar]
  210. SpinaE. TrifiròG. CaraciF. BrunoA. Clinically significant drug interactions with newer antidepressants.CNS Drugs2016304269287 26968404
     [Google Scholar]
  211. HaslemoT. EikesethP.H. TanumL. MoldenE. RefsumH. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.Eur. J. Clin. Pharmacol.2018742181188 29080058
     [Google Scholar]
  212. BertzR.J. GrannemanG.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.Clin. Pharmacokinet.199732321025810.2165/00003088‑199732030‑00004 9084960
     [Google Scholar]
  213. PirmohamedM. ParkB.K. Genetic susceptibility to adverse drug reactions.Trends Pharmacol. Sci.200122629830510.1016/S0165‑6147(00)01717‑X 11395158
     [Google Scholar]
  214. RowlandM. TozerT.N. Clinical pharmacokinetics and pharmacodynamics: Concepts and applications.Lippincott Williams & Wilkins2010
     [Google Scholar]
  215. WojcikowskiJ. DanielW.A. The role of the blood–brain barrier efflux transporters in brain distribution of antidepressant drugs.Curr. Pharm. Des.2013193460556069
     [Google Scholar]
  216. HicksJ.K. BishopJ.R. SangkuhlK. Clinical pharmacogenetics implementation consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors.Clin. Pharmacol. Ther.201598212713410.1002/cpt.147 25974703
     [Google Scholar]
  217. HicksJ.K. SwenJ.J. ThornC.F. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.Clin. Pharmacol. Ther.201393540240810.1038/clpt.2013.2 23486447
     [Google Scholar]
  218. Saiz-RodríguezM. MagriC. MinelliA. ValsecchiP. The role of pharmacogenomics in the treatment of depression.Pharmacogenomics J.2016162146155 26856250
     [Google Scholar]
  219. de LeonJ. MargaretT.S. Murray-CarmichaelE. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.Mol. Diagn. Ther.2009136399404 16771600
     [Google Scholar]
  220. BauerM. SeverusE. MöllerH.J. YoungA.H. Pharmacological treatment of unipolar depressive disorders: Summary of WFSBP guidelines.Int. J. Psychiatry Clin. Pract.20131715059 28367707
     [Google Scholar]
  221. NuttD.J. Overview of diagnosis and drug treatments of anxiety disorders.CNS Spectr.2005101495610.1017/S1092852900009901 15618947
     [Google Scholar]
  222. RapaportM.H. GharabawiG.M. CanusoC.M. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.Neuropsychopharmacology200631112505251310.1038/sj.npp.1301113 16760927
     [Google Scholar]
  223. FergusonJ.M. ShingletonR. AnzianoR. ArchibaldD. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).J. Clin. Psychopharmacol.2014342163171
     [Google Scholar]
  224. CuijpersP. van StratenA. WarmerdamL. AnderssonG. Psychological treatment of depression: A meta-analytic database of randomized studies.BMC Psychiatry2008813610.1186/1471‑244X‑8‑36 18485191
     [Google Scholar]
  225. MammenG. FaulknerG. Physical activity and the prevention of depression: A systematic review of prospective studies.Am. J. Prev. Med.201345564965710.1016/j.amepre.2013.08.001 24139780
     [Google Scholar]
  226. SegalZ.V. WilliamsJ.M.G. TeasdaleJ.D. Mindfulness-based cognitive therapy for depression: A new approach to preventing relapse.Guilford Press2002
     [Google Scholar]
  227. SarrisJ. O’NeilA. CoulsonC.E. SchweitzerI. BerkM. Lifestyle medicine for depression.BMC Psychiatry201414110710.1186/1471‑244X‑14‑107 24721040
     [Google Scholar]
  228. ZajeckaJ.M. RossJ.S. Treating depression to remission: Targeting the full functional impact.J. Clin. Psychiatry2017785e559e9 28570794
     [Google Scholar]
  229. TrivediM.H. RushA.J. WisniewskiS.R. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.Am. J. Psychiatry20061631284010.1176/appi.ajp.163.1.28 16390886
     [Google Scholar]
  230. GartlehnerG. GaynesB.N. HansenR.A. ThiedaP. DeVeaugh-GeissA. KrebsE.E. Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians.Ann. Intern. Med.20111551177278510.7326/0003‑4819‑155‑11‑201112060‑00009 22147715
     [Google Scholar]
  231. BauerM. PfennigA. SeverusE. WhybrowP.C. AngstJ. MöllerH.J. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders.World J. Biol. Psychiatry201314533438510.3109/15622975.2013.804195 23879318
     [Google Scholar]
  232. FavaM. RushA.J. TrivediM.H. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.Psychiatr. Clin. North Am.2003262457494, x10.1016/S0193‑953X(02)00107‑712778843
     [Google Scholar]
  233. QuitkinF.M. McGrathP.J. StewartJ.W. TaylorB.P. TisminetzkyM.S. PetkovaE. Phenelzine and imipramine in mood-incongruent psychotic depressive disorder: An acute placebo-controlled trial.Am. J. Psychiatry1993150811821189 8328561
     [Google Scholar]
  234. ThaseM.E. EntsuahA.R. RudolphR.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.Br. J. Psychiatry2001178323424110.1192/bjp.178.3.234 11230034
     [Google Scholar]
  235. GartlehnerG.H. HansenR.A. ReichenpfaderU.K. Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report Drug Class Reviews.PortlandOregon Health and Science University2011
     [Google Scholar]
  236. BeckA.T. RushA.J. ShawB.F. EmeryG. Cognitive therapy of depression.Guilford Press1979
     [Google Scholar]
  237. KlermanG.L. WeissmanM.M. RounsavilleB.J. ChevronE.S. Interpersonal psychotherapy of depression.Basic Books1984
     [Google Scholar]
  238. MuraG. MoroM.F. PattenS.B. CartaM.G. Exercise as an add-on strategy for the treatment of major depressive disorder: A systematic review.CNS Spectr.201419649650810.1017/S1092852913000953 24589012
     [Google Scholar]
  239. HofmannS.G. SawyerA.T. WittA.A. OhD. The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review.J. Consult. Clin. Psychol.201078216918310.1037/a0018555 20350028
     [Google Scholar]
  240. JackaF.N. O’NeilA. OpieR. A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial).BMC Med.20171512310.1186/s12916‑017‑0791‑y 28137247
     [Google Scholar]
  241. Mozaffari-KhosraviH. NabizadeL. Yassini-ArdakaniS.M. HadinedoushanH. BarzegarK. The effect of 2 different single injections of high dose of vitamin D on improving the depression in depressed patients with vitamin D deficiency: A randomized clinical trial.J. Clin. Psychopharmacol.201333337838510.1097/JCP.0b013e31828f619a 23609390
     [Google Scholar]
  242. RiemannD. VoderholzerU. Primary insomnia: A risk factor to develop depression?J. Affect. Disord.2003761-325525910.1016/S0165‑0327(02)00072‑1 12943956
     [Google Scholar]
  243. National Institute on Drug AbuseDrugs, Brains, and Behavior: The Science of Addiction.Available from: https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/introduction 2020
  244. MalbergJ.E. BlendyJ.A. Antidepressant action: to the nucleus and beyond.Trends Pharmacol. Sci.2005261263163810.1016/j.tips.2005.10.005 16246434
     [Google Scholar]
  245. SchatzbergA.F. NemeroffC.B. The American Psychiatric Association Publishing textbook of psychopharmacology.American Psychiatric Pub.201710.1176/appi.books.9781615371624
     [Google Scholar]
  246. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder.Am. J. Psychiatry20131574145
     [Google Scholar]
  247. Lorenzo-LuacesL. ZimmermanM. CuijpersP. BocktingC. Methodological limitations in meta-analyses obscure associations between the efficacy of psychotherapy and nonspecific factors.Clin. Psychol.2018713436441
     [Google Scholar]
  248. National Institute for Health and Care Excellence (NICE)Depression in adults: Recognition and management. Clinical Guideline [CG90].Available from: https://www.nice.org.uk/guidance/cg90 2018
  249. ElwynG. FroschD. ThomsonR. Shared decision making: A model for clinical practice.J. Gen. Intern. Med.201227101361136710.1007/s11606‑012‑2077‑6 22618581
     [Google Scholar]
  250. CharlesC. GafniA. WhelanT. Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango).Soc. Sci. Med.199744568169210.1016/S0277‑9536(96)00221‑3 9032835
     [Google Scholar]
  251. HaggertyJ.L. ReidR.J. FreemanG.K. StarfieldB.H. AdairC.E. McKendryR. Continuity of care: A multidisciplinary review.BMJ200332774251219122110.1136/bmj.327.7425.1219 14630762
     [Google Scholar]
  252. BrownC.E. EcoffL. A review of the evidence on interdisciplinary rounds to improve communication, collaboration, and patient outcomes.J. Nurs. Adm.2018483172178
     [Google Scholar]
  253. JonesA. SimmonsB. The benefits of interdisciplinary communication: a guide to successful interactions for academic librarians.J. Acad. Librariansh.2016426668672
     [Google Scholar]
  254. JohnsonJ.K. Factors associated with understanding of precautionary labels among parents of pediatric patients.The Med. j. Australia201519811621623
     [Google Scholar]
  255. GrayR.E. Medication side effects: The elephant in the room in primary care practice.J. Fam. Pract.20166511738744
     [Google Scholar]
  256. DesaiP.R. Exploring the relationship between medication side effects and the functional limitations of older adults.J. Aging Health201931711431160
     [Google Scholar]
  257. BrownM.T. BussellJ.K. Medication adherence: WHO cares?Mayo Clin. Proc.201186430431410.4065/mcp.2010.0575 21389250
     [Google Scholar]
  258. ErnstF.R. Antidepressant medication adherence and generic equivalency: findings from the 2002 medical expenditure panel survey.J. Manag. Care Pharm.2015114323329
     [Google Scholar]
  259. BultmanD.C. SvarstadB.L. Effects of physician communication style on client medication beliefs and adherence with antidepressant treatment.Patient Educ. Couns.200040217318510.1016/S0738‑3991(99)00083‑X 10771371
     [Google Scholar]
  260. TrenamanL. BryanK. The patient–practitioner relationship in medication management: Insights from experienced practitioners.Health Soc. Care Community2008165530537
     [Google Scholar]
  261. KörnerM. SarahB. ChristianM. ZimmermannL. Interprofessional teamwork and team interventions in chronic care: A systematic review.J. Interprof. Care2010246513526 26709985
     [Google Scholar]
  262. ReevesS. PeloneF. HarrisonR. GoldmanJ. ZwarensteinM. Interprofessional collaboration to improve professional practice and healthcare outcomes.Cochrane Libr.201720188CD00007210.1002/14651858.CD000072.pub3 28639262
     [Google Scholar]
  263. XyrichisA. LowtonK. What fosters or prevents interprofessional teamworking in primary and community care? A literature review.Int. J. Nurs. Stud.200845114015310.1016/j.ijnurstu.2007.01.015 17383655
     [Google Scholar]
  264. LingardL. EspinS. WhyteS. RegehrG. BakerG.R. Communication failures in the operating room: An observational classification of recurrent types and effects.Qual. Saf. Health Care20021113034 15465935
     [Google Scholar]
/content/journals/cds/10.2174/0115748863301630240417071353
Loading
From Evidence to Practice: A Comprehensive Analysis of Side Effects in Synthetic Anti-Depressant Therapy
Curr Drug Saf 20, 120 (2025); https://doi.org/10.2174/0115748863301630240417071353
/content/journals/cds/10.2174/0115748863301630240417071353
/content/journals/cds/10.2174/0115748863301630240417071353
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Antidepressant medications; clinical implications; pharmacogenetics; side-effects; treatment strategies; tricyclic antidepressants (TCAs)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test